BERLIN, Germany, May 8th, 2019 – Chinook Tyee Industry Limited (“Chinook”) (TSXV: XCX) (FSE: C4T), has granted incentive stock options to purchase up to 1,020,000 common shares of Chinook to its directors, officers, employees, and consultants in Germany, Switzerland and Canada pursuant to its stock option plan, including 655,000 options issued to directors and officers. Each option vests immediately, has an exercise price of $0.15 per share and is valid for a period of one year from the date of issuance.
{{cta(’69f63bd3-e695-415f-8c83-b207c29317a6′)}} {{cta(‘8bda15e4-5341-4195-a3c9-920630e5666d’)}}
Chinook Tyee Industry Limited Chinook is a Berlin based investment company with two European subsidiaries, AMP Alternative Medical Products GmbH (AMP Germany) and Mercury Partners & Company plc. AMP Germany plans to import pharmaceutical grade (EU-GMP) cannabis produced by Canadian licensed producers into Germany. AMP Germany, in cooperation with its business partners, will provide EU-GMP audit, logistical, transportation, importation and other related services for the importation of medical cannabis into Germany. Mercury Partners & Company plc is a Malta based investment holding company that invests mainly in German distressed assets. Chinook has 10,217,796 shares outstanding and trades on the TSX Venture Exchange (symbol: “XCX”) and the Frankfurt Stock Exchange (symbol: “C4T”). www.amp-eu.com.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Canada Mr. Alex Blodgett, Director Tel: +1 (236) 833-1602 Email: investor@amp-eu.com
Germany Email: investor@amp-eu.de
Social media links: Twitter, Reddit, LinkedIN
SOURCE Chinook Tyee Industry Limited